Home / Resources
Resources
DILI Uncovered: how to mitigate hepatoxicity failure
Explore the challenges of predicting drug-induced liver injury (DILI) during preclinical development and discover how emerging in vitro approaches can support earlier, more informed safety assessment. This on-demand webinar examines key biological mechanisms behind DILI, current limitations in detection strategies, and evolving scientific perspectives shaping the future of hepatotoxicity evaluation.
Interviews
12.06.25
Insights into drug discovery and development 2025
Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
Interviews
16.12.24
Meet the Organix Director, Mario Gonzalez
We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
Interviews
18.01.23
An interview with Yadan Chen and Paul O’Shea
We are pleased to introduce the founders of Symeres’ daughter company Exemplify in New Jersey: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
Interviews
02.08.22
An interview with Anu Mahadevan and Paul Blundell
We proudly introduce the founders of Symeres’ daughter company Organix in Boston: Anu Mahadevan, CEO, and Paul Blundell, President at Organix. Who are they? What do they stand for? And how does Organix fit with Symeres?
Speak with our discovery and development experts
See how we can support the discovery and development of your next breakthrough.